Combined Upadacitinib and Vedolizumab as 8-Week Induction Therapy for Moderate-to-Severe Ulcerative Colitis: A Multicenter, Randomized Controlled Trial - PubMed
2 hours ago
- #combination therapy
- #ulcerative colitis
- #clinical trial
- The study evaluated an 8-week induction combination therapy (upadacitinib + vedolizumab) vs. vedolizumab monotherapy for moderate-to-severe ulcerative colitis.
- Primary endpoint was endoscopic remission at week 8, with results showing 37.5% remission for combination vs. 15.1% for monotherapy (P = .010).
- Clinical remission and histologic-endoscopic mucosal improvement rates were significantly higher in the combination group.
- Adverse event rates were comparable between groups, with no serious adverse events reported.
- Conclusions suggest the combination therapy is superior, though caution is advised due to early trial termination and open-label design.